Silverman, Stuart L.
Siris, E.
Belazi, D.
Recknor, C.
Papaioannou, A.
Brown, J. P.
Gold, D. T.
Lewiecki, E. M.
Quinn, G.
Balasubramanian, A.
Yue, S.
Stolshek, B.
Kendler, D. L.
Article History
Received: 10 January 2018
Accepted: 18 June 2018
First Online: 7 August 2018
Compliance with ethical standards
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and/or ethics committee at each clinical practice and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: S.L. Silverman is a speaker for Lilly, Amgen, and Radius; is a consultant for Amgen; has received research grants from Lilly and Amgen; and has participated in advisory boards for Amgen and Radius. E. Siris was a consultant for Amgen, Merck, and Radius. D. Belazi has no conflict of interest or disclosures. C. Recknor has received research support from Amgen and Eli Lilly. A. Papaioannou has received consulting fees and grants from Amgen. J.P. Brown has received grants/research support from Amgen and Eli Lilly; has received consulting fees from Amgen, Eli Lilly, and Merck; and speakers’ bureau honorarium from Amgen and Eli Lilly. D.T. Gold has received consulting fees from Amgen, Eli Lilly, and Radius. E.M. Lewiecki has received grants/research support from Amgen and consulting fees from Amgen and Radius. G. Quinn has received consulting fees from Amgen. A. Balasubramanian, S. Yue, and B. Stolshek are employees and shareholders of Amgen Inc. D.L. Kendler has received research grants from Amgen, AstraZeneca, and Eli Lilly; is a consultant for Amgen, Pfizer, and Eli Lilly; and has received speakers’ honoraria from Amgen and Eli Lilly.